Australia will soon be joining the medical cannabis revolution. Its federal government has moved to legalize marijuana for medical and scientific purposes, and a Roy Morgan Research poll shows that 91 percent of Australians agree that medical marijuana should be legalized.
The poll, which was released on Monday, asked 644 Australians 14 years of age or older whether the use of marijuana for medical purposes should be made legal or not, with only 7 percent not voting in favor.
Roy Morgan Research CEO Michele Levine told The Guardian that she was not surprised to find the strongest support from those aged 50 and older, as “[t]his group is most susceptible to several of the conditions that medicinal marijuana can provide relief from: Parkinson’s disease, cancer, glaucoma and more.”
The poll results were released less than two weeks after Australia’s federal government announced plans to amend the Narcotic Drug Act 1967 to allow cannabis to be grown for medical and scientific purposes, without breaching international drug treaties.
“This Government is incredibly sympathetic to the suffering of those Australians with debilitating illnesses and we want to enable access to the most effective medical treatments available,” Health Minister Sussan Ley said in a statement.

Under current Australian laws, marijuana is classified as an illegal drug, and while penalties vary from state to state, the growth, use, possession or sale of it is punishable by a fine or jail time.
Even so, some Australian states are already taking steps toward medical marijuana research and development. For example, the New South Wales government just announced that it is committed to spending $9 million to support medical cannabis clinical trials for terminally ill adult cancer patients, making it the first Australian state to do so.
The government of Victoria is taking a slightly different route. It’s looking to legalize access to locally manufactured medical cannabis products for patients with exceptional circumstances and severe symptoms from 2017 onward.
While the individual states don’t have the authority to set rules for the cultivation of cannabis and production of medical marijuana products, the move by the federal government will make it easier.

Medical marijuana stocks

As it stands, there are only three medical marijuana companies listed on the ASX, and two of them are transformed mining companies. The three companies are as follows: MMJ Phytotech (ASX:MMJ), Erin Resources (ASX:ERI) and the most recent addition to the roster, Capital Mining (ASX:CMY).
MMJ Phytotech completed a $15.5-million merger with Canadian MMJ Bioscience in June to become the first ASX-listed medical marijuana company. The company has been working to accelerate its entry into the Australian medical cannabis market, completing a $2-million share placement and beginning a Phase 1 clinical trial of tetrahyrocannabidiol (THC) and cannabidiol (CDB) oral capsules for the treatment of pain and spasticity in multiple sclerosis patients following the federal government’s announcement.

Then there is Erin Resources, a gold explorer that completed a reverse takeover of Israel-based MGC Pharmaceuticals in August; MGC is a medical and cosmetic cannabis company that received two licenses in June to grow, process and trade its cannabis products in Europe.
Capital Mining, the third company, is currently in the process of entering the Australian medical marijuana market through the acquisition of a group of US and Canadian companies, including Denver-based Nutrawerx, Canadian Broken Coast Cannabis and Cannan Growersone.
Those interested in the medical cannabis space will no doubt be watching to see how legalization in Australia moves ahead and what other companies move into the ever-growing market moving forward.
Securities Disclosure: I, Kristen Moran, hold no direct investment interest in any company mentioned in this article.
Related reading: 
Legal Cannabis Stocks in North America
How to Invest in Medical Cannabis
Legalizing Medical Cannabis: A Look at the Laws Surrounding Medical Marijuana

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less